Cryoport, Inc.
Cryoport, Inc is a global life sciences logistics company that provides cryogenic transportation services for the pharmaceutical industry
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cryoport's stock with a target price of $13, indicating growth potential.
Financial Health
Cryoport is performing well with strong revenue and cash flow, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CYRX
Supply Chain Stocks: May Tariff Impacts Drive Growth?
The continued contraction of the U.S. manufacturing sector, heavily influenced by tariff wars, underscores the challenges facing domestic producers. This environment may create investment opportunities in companies that provide solutions for supply chain optimization and cost reduction.
Published: September 3, 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketSupplying The Grocery Wars
Amazon is aggressively expanding its same-day fresh grocery delivery service, intensifying competition with rivals like Instacart and Walmart. This move creates a significant investment opportunity in the logistics, warehouse automation, and cold chain companies that support this large-scale fulfillment network.
Published: August 14, 2025
Explore BasketThe Froneri Effect: Investing In The Ice Cream Supply Chain
Investment giant Goldman Sachs is acquiring a major stake in ice cream maker Froneri, signaling strong confidence in the consumer packaged goods space. This move creates a potential growth opportunity for companies supplying ingredients, packaging, and logistics to the expanding frozen dessert market.
Published: August 1, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Biologics cold chain
Demand for cell and gene therapies supports long‑term market growth, though commercialisation timelines and adoption can vary and affect revenue.
Global network expansion
Partnerships and international hubs can drive recurring revenues and scale benefits, but regulatory complexity and logistics risks remain.
Execution and competition
Scalability and operational reliability are critical; competition and capital needs can pressure margins, underscoring execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Union Pacific Corporation
Operates in the railroad industry
United Parcel Service, Inc.
Provides delivery and logistics services
CSX Corp.
CSX is a transportation company operating a freight rail system in the eastern United States
